UBS turns positive on Coloplast, citing overstated risks

Coloplast A/S

24/03/2026 13:23

** UBS upgrades Coloplast COLOb.CO to "buy" from "neutral", saying market concerns appear overstated as the stock has hit 10-year lows

** The brokerage says recent revenue underperformance and margin contraction are driven by the maturing business rather than deteriorating fundamentals

** "Business isn't broken, it's just maturing," it says, seeing ample scope for new CEO Gavin Wood to deliver quick wins including portfolio simplification

** UBS says fears around competitive bidding and acquired wound-care unit Kerecis are overstated, with the company poised for above-sector revenue and earnings growth

** PT is unchanged at DKK 530, as UBS sees a 50% increase in return on invested capital by 2030 and a potential re-rating after Coloplast's more detailed update, expected in August

** Out of 23 analysts that cover the stock, four rate it "strong buy" or "buy", 16 "hold" and three "sell" - LSEG data

(Reporting by Marta Frackowiak)

((marta.frackowiak@thomsonreuters.com))